- Home
- IMUX vs CGO Comparison
IMUX vs CGO Comparison
Compare IMUX & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- CGO
- Stock Information
- Founded
- IMUX 2016
- CGO 2004
- Country
- IMUX United States
- CGO United States
- Employees
- IMUX N/A
- CGO N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- CGO Investment Managers
- Sector
- IMUX Health Care
- CGO Finance
- Exchange
- IMUX Nasdaq
- CGO Nasdaq
- Market Cap
- IMUX 90.3M
- CGO 105.3M
- IPO Year
- IMUX N/A
- CGO N/A
- Fundamental
- Price
- IMUX $0.98
- CGO $9.82
- Analyst Decision
- IMUX Strong Buy
- CGO
- Analyst Count
- IMUX 6
- CGO 0
- Target Price
- IMUX $13.20
- CGO N/A
- AVG Volume (30 Days)
- IMUX 661.4K
- CGO 34.7K
- Earning Date
- IMUX 05-07-2025
- CGO 01-01-0001
- Dividend Yield
- IMUX N/A
- CGO 9.25%
- EPS Growth
- IMUX N/A
- CGO N/A
- EPS
- IMUX N/A
- CGO N/A
- Revenue
- IMUX N/A
- CGO N/A
- Revenue This Year
- IMUX N/A
- CGO N/A
- Revenue Next Year
- IMUX N/A
- CGO N/A
- P/E Ratio
- IMUX N/A
- CGO N/A
- Revenue Growth
- IMUX N/A
- CGO N/A
- 52 Week Low
- IMUX $0.83
- CGO $7.90
- 52 Week High
- IMUX $2.11
- CGO $10.93
- Technical
- Relative Strength Index (RSI)
- IMUX 45.24
- CGO 44.33
- Support Level
- IMUX $0.86
- CGO $9.70
- Resistance Level
- IMUX $1.01
- CGO $10.20
- Average True Range (ATR)
- IMUX 0.09
- CGO 0.40
- MACD
- IMUX -0.01
- CGO 0.04
- Stochastic Oscillator
- IMUX 42.53
- CGO 64.16
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.